Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?

Drug and Alcohol Dependence

Volumn 144, Issue , 2014, Pages 42-46

  Kelly, Meredith A ^a,b   Pavlicova, Martina ^c   Glass, Andrew ^d   Mariani, John J ^a,b   Bisaga, Adam ^a,b   Sullivan, Maria A ^a,b   Nunes, Edward V ^a,b   Levin, Frances R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

^c Columbia University ^*  (United States)

^d Division of Biostatistics in the Department of Psychiatry   (United States)

Author keywords

Cannabis; Cannabis withdrawal; Marijuana; Marijuana withdrawal; Treatment; Venlafaxine

Indexed keywords

DRONABINOL; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE;

ABNORMAL DREAMING; ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CANNABIS USE; CHECKLIST; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MARIJUANA WITHDRAWAL CHECKLIST SCORE; MENTAL INSTABILITY; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SECONDARY ANALYSIS; SLEEP DISORDER; SMOKING CESSATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYMPTOMATOLOGY; URINALYSIS; WITHDRAWAL SYNDROME; ADOLESCENT; COMPLICATION; DEPRESSIVE DISORDER; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

CANNABIS; CANNABIS SATIVA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 84909981958     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.06.040     Document Type: Article

References (20)

1. Allsop D.J., Copeland J., Norberg M.M., Fu S., Molnar A., Lewis J., Budney A.J. Quantifying the clinical significance of cannabis withdrawal. PLoS ONE 2012, 7:e44864.
2. Anggadiredja K., Yamaguchi T., Tanaka H., Shoyama Y., Watanabe S., Yamamoto T. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice. Brain Res. 2003, 966:47-53.
3. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 1986, 51:1173-1182.
4. Budney A.J., Higgins S.T., Radonovich K.J., Novy P.L. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J. Consult. Clin. Psychol. 2000, 68:1051-1061.
5. Budney A.J., Moore B.A., Rocha H.L., Higgins S.T. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J. Consult. Clin. Psychol. 2006, 74:307-316.
6. Budney A.J., Vandrey R.G., Hughes J.R., Thostenson J.D., Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J. Subst. Abuse Treat. 2008, 35:362-368.
7. Carpenter K.M., McDowell D., Brooks D.J., Cheng W.Y., Levin F.R. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am. J. Addict. 2009, 18:53-64.
8. Cornelius J.R., Chung T., Martin C., Wood D.S., Clark D.B. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict. Behav. 2008, 33:1500-1505.
9. Haney M., Cooper Z.D., Bedi G., Vosburg S.K., Comer S.D., Foltin R.W. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 2013, 38:1557-1565.
10. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Foltin R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008, 197:157-168.
11. Haney M., Ward A.S., Comer S.D., Hart C.L., Foltin R.W., Fischman M.W. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl) 2001, 155:171-179.
12. Harvey A.T., Rudolph R.L., Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry 2000, 57:503-509.
13. Hasin D.S., Keyes K.M., Alderson D., Wang S., Aharonovich E., Grant B.F. Cannabis withdrawal in the United States: results from NESARC. J. Clin. Psychiatry 2008, 69:1354-1363.
14. Imai K., Keele L., Tingley D. A general approach to causal mediation analysis. Psychol. Methods 2010, 15:309-334.
15. Levin F.R., Mariani J., Brooks D.J., Pavlicova M., Cheng C., Nunes E. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011, 116:142-150.
16. Levin F.R., Mariani J., Brooks D.J., Pavlicova M., Nunes E.V., Agosti V., Bisaga A., Sullivan M.A., Carpenter K.M. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 2013, 108:1084-1094.
17. Lichtman A.H., Fisher J., Martin B.R. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine. Pharmacol. Biochem. Behav. 2001, 69:181-188.
18. Mason B.J., Crean R., Goodell V., Light J.M., Quello S., Shadan F., Buffkins K., Kyle M., Adusumalli M., Begovic A., et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012, 37:1689-1698.
19. Tirado C.F., Goldman M., Lynch K., Kampman K.M., Obrien C.P. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend. 2008, 94:254-257.
20. UNODC World Drug Report 2011, http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf.